JP6767647B2 - 炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤 - Google Patents

炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤 Download PDF

Info

Publication number
JP6767647B2
JP6767647B2 JP2017519617A JP2017519617A JP6767647B2 JP 6767647 B2 JP6767647 B2 JP 6767647B2 JP 2017519617 A JP2017519617 A JP 2017519617A JP 2017519617 A JP2017519617 A JP 2017519617A JP 6767647 B2 JP6767647 B2 JP 6767647B2
Authority
JP
Japan
Prior art keywords
cells
slc5a12
lactate
antibody
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017519617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532332A5 (https=
JP2017532332A (ja
Inventor
マウロ、クラウディオ
ハース、ロバート
マレリ−バーグ、フェデリカ
Original Assignee
クイーン メアリー ユニバーシティ オブ ロンドン
クイーン メアリー ユニバーシティ オブ ロンドン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クイーン メアリー ユニバーシティ オブ ロンドン, クイーン メアリー ユニバーシティ オブ ロンドン filed Critical クイーン メアリー ユニバーシティ オブ ロンドン
Publication of JP2017532332A publication Critical patent/JP2017532332A/ja
Publication of JP2017532332A5 publication Critical patent/JP2017532332A5/ja
Application granted granted Critical
Publication of JP6767647B2 publication Critical patent/JP6767647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
JP2017519617A 2014-10-20 2015-10-20 炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤 Active JP6767647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1418626.6A GB201418626D0 (en) 2014-10-20 2014-10-20 Method
GB1418626.6 2014-10-20
PCT/GB2015/053125 WO2016063037A1 (en) 2014-10-20 2015-10-20 Inhibitors of lactate transporters for use in the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2017532332A JP2017532332A (ja) 2017-11-02
JP2017532332A5 JP2017532332A5 (https=) 2018-11-22
JP6767647B2 true JP6767647B2 (ja) 2020-10-14

Family

ID=52013297

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519617A Active JP6767647B2 (ja) 2014-10-20 2015-10-20 炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤

Country Status (6)

Country Link
US (3) US20170355987A1 (https=)
EP (1) EP3209328B1 (https=)
JP (1) JP6767647B2 (https=)
CA (1) CA2962798C (https=)
GB (1) GB201418626D0 (https=)
WO (1) WO2016063037A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735427A4 (en) * 2018-01-05 2021-09-15 Immunext Inc. ANTI-MCT1 ANTIBODIES AND USES THEREOF
IL298522A (en) * 2020-05-29 2023-01-01 Univ Rockefeller Markers and progenitor cells of rheumatoid arthritis flares
CN115300627B (zh) * 2021-05-08 2024-01-26 中南大学湘雅医院 钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
TWI842088B (zh) * 2021-09-14 2024-05-11 美商伊穆諾米塔博立森發展公司 人類單羧酸鹽轉運蛋白1抗體及其用途
CN117430697A (zh) * 2022-07-21 2024-01-23 佰舟生物科技(苏州)有限公司 抗mct1抗体及其用途
CN121102184A (zh) * 2025-09-15 2025-12-12 中南大学湘雅医院 一种SerpinB3抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) * 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2010089580A1 (en) * 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
GB201016494D0 (en) 2010-09-30 2010-11-17 Queen Mary Innovation Ltd Polypeptide
KR20120123748A (ko) * 2011-04-29 2012-11-12 원광대학교산학협력단 플로레틴을 포함하는 글루타치온 ｓ―전이효소 유도 및 사이토크롬 ｐ450 효소 억제용 조성물

Also Published As

Publication number Publication date
JP2017532332A (ja) 2017-11-02
US20190106697A1 (en) 2019-04-11
CA2962798C (en) 2024-04-16
CA2962798A1 (en) 2016-04-28
EP3209328B1 (en) 2021-09-01
US20170355987A1 (en) 2017-12-14
GB201418626D0 (en) 2014-12-03
US20210087561A1 (en) 2021-03-25
EP3209328A1 (en) 2017-08-30
WO2016063037A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US20240190953A1 (en) Il-11 antibodies
JP6767647B2 (ja) 炎症性疾患の治療に使用するための乳酸トランスポーターの阻害剤
US11813311B2 (en) Treatment and prevention of metabolic diseases
CA2887528C (en) Enhancement of the immune response
TW201006485A (en) Dual variable domain immunoglobulins and uses thereof
TW201119676A (en) Dual variable domain immunoglobulins and uses thereof
TW201127956A (en) Dual variable domain immunoglobulins and uses thereof
KR20130133247A (ko) Ｉｌ-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도
TW201008580A (en) Dual variable domain immunoglobulin and uses thereof
US20260055176A1 (en) Anti-il-27 antibodies and uses thereof
TW201109438A (en) Dual variable domain immunoglobulins and uses thereof
TW201241180A (en) Dual variable domain immunoglobulins and uses thereof
TW201211252A (en) Dual variable domain immunoglobulins and uses thereof
TW201124534A (en) Dual variable domain immunoglobulins and uses thereof
JP6990674B2 (ja) 黄色ブドウ球菌ロイコシジンの細胞毒性に関与する細胞因子：新規治療標的
TW201623330A (zh) Ｉｌ－２１抗體
TW202019477A (zh) BCMAxCD3抗體構建體之給藥方案
KR20160117643A (ko) 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
BR112020020118A2 (pt) composto anti-cmklr1, molécula de ácido nucleico, vetor, célula hospedeira, produto de combinação, combinação de composto, método para selecionar um composto anti-cmklr1, e, composto agonista de cmklr1.
TW202409280A (zh) Cnx抗原結合分子
SG11202111742QA (en) Methods of diagnosis and treatment of rheumatoid arthritis
JP2026502391A (ja) 腫瘍を処置する方法
권희성 A bispecific antibody targeting tumor necrosis factor-α (TNF-α) and OX40 ligand (OX40L) demonstrates superior efficacy in the treatment of rheumatoid arthritis
JP2010116338A (ja) 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200819

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200827

R150 Certificate of patent or registration of utility model

Ref document number: 6767647

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250